






Figure S1. Enrichment of CD45⁻ LN stromal cells for scRNA-seq. (A-E) WT C57BL/6 mice were mock-inoculated (n = 2) or inoculated in both rear footpads with 10³ PFU CHIKV (n = 2). The left and right popliteal LNs were collected at 8 h post-infection for enrichment of CD45⁻ LN stromal cells (LNSCs) via depletion of CD45⁺ cells. The proportion of CD45⁺ and CD45⁻ cells was evaluated pre- and post-depletion by flow cytometry. (A) Representative flow cytometry plots showing the gating strategy for live CD45⁻ LNSCs. (B and C) Representative flow cytometry plots of live cell viability (B) and percentage of CD45⁻ cells (C) in mock and CHIKV-infected samples pre- and post-CD45⁺ cell depletion. (D and E) Percentage of CD45⁺ and CD45⁻ cells in each condition and replicate pre- (D) and post-(E) CD45⁺ cell depletion.


A



B



C



D








Figure S2. Cell type annotation of scRNA-seq data. WT C57BL/6 mice were inoculated with PBS (mock, n = 3) or 10^3 PFU of CHIKV (n = 3) in the left-rear footpad. At 8 and 24 h post-infection, the dLN was collected and enzymatically digested into a single-cell suspension. Cells were enriched for CD45⁺ cells and analyzed by scRNA-seq as previously described (34). **(A)** UMAP projections of cell type annotations for integrated data. **(B)** UMAP projections of endothelial cell type annotations for integrated data. **(C)** Correlation between annotated LEC subsets and reference data. **(D)** Expression of select marker genes across LN cells.


A




B




C



E



D



F




Figure S3. Signs of CHIKV RNA replication in MARCO-expressing LECs. (A-E) WT C57BL/6 mice were inoculated with PBS (mock, n = 3-6) or 10^3 PFU of CHIKV (n = 3-8) in the left-rear footpad. At 24 h post-infection, the dLN was collected and enzymatically digested into a single-cell suspension. Cell suspensions were either enriched for CD45⁻ cells and analyzed by scRNA-seq as previously described (34) or analyzed for cell viability by flow cytometry. **(A)** UMAP projection shows annotated cell types. **(B)** UMAP projection shows CHIKV sgRNA ratio (number of sgRNA reads/number of 5' reads). **(C)** The fraction of cells identified as CHIKV-high is shown for each cell type. Labels show the number of CHIKV-high cells/total cells. P values were calculated as described in **Figure 1D**. **(D)** CHIKV sgRNA ratio for cells with >0 sgRNA reads and >0 5' reads. Only cell types with >40 cells are shown. P values were calculated using a two-sided Wilcoxon rank sum test with Bonferroni correction. **(E)** The correlation between CHIKV sgRNA ratio and QC metrics for CHIKV-high MARCO⁺ LECs and unassigned-LECs. **(F)** LN LEC viability at 1 d post-infection was determined by flow cytometric analysis of cell populations stained with a live-dead cell viability dye. ****, $P < 0.000$, student's t-test (2 independent experiments).




Figure S4. Lyve-1 and MARCO expression over time during WT and attenuated CHIKV infection. (A-C) WT C57BL/6 mice were mock-inoculated ($n = 3$) or inoculated in the footpad with 10^3 PFU CHIKV 181/25 ($n = 5$) or WT CHIKV ($n = 5$). At 8 (A), 24 (B), or 48 (C) h post-infection the dLN was collected. Frozen dLN sections were stained for B220 (B cells; blue), Lyve-1 (LECs; white), and MARCO (red). Scale bar, 200 μ m. Images are representative of 3-5 dLNs per group (2 independent experiments).




Figure S5. Impaired antigen acquisition is LEC-specific and not limited to the popliteal LN.

WT C57BL/6 mice were mock-infected or infected in the footpad with 10^3 PFU CHIKV 181/25 or WT CHIKV. At 72 h post-infection, mice were inoculated with 10 μ g ova-488 in both calf muscles (20 μ g total), and ova⁺ LNSCs in the popliteal and iliac LNs were then evaluated by flow cytometry at the indicated timepoints. As a positive control, naïve mice were injected with 10 μ g ova-488 and 5 μ g polyI:C in both calf muscles. Representative plots showing ova⁺ LNSCs in the popliteal LN (**A**). Percentage of ova⁺ BECs, FRCs, and LECs among each condition in the popliteal LN.

(**B**) LNSC numbers in the iliac LN following ova immunization (**C**). Representative plots showing ova⁺ LECs in the iliac LN, including the naïve control for gating on ova⁺ LECs (**D**) and quantification of percentage and number of ova⁺ LECs (**E**). Only statistical comparison of ova⁺ BECs, FRCs, and LECs within each condition is shown. ***, $P < 0.01$; ****, $P < 0.0001$, one or two-way ANOVA with Tukey's multiple comparison test (2 independent experiments).